| N (%) |
---|---|
Patients receiving other pharmacological therapies for psoriatic arthritis or psoriasis during the observation period | 186 (46.6%) |
Methotrexate | 112 (28.1%) |
NSAIDs | 49 (12.3%) |
Systemic corticosteroids (oral or parenteral) | 43 (10.8%) |
Leflunomide | 18 (4.5%) |
Sulfasalazine | 15 (3.8%) |
Cyclosporine | 7 (1.8%) |
Apremilast | 4 (1.0%) |
Azathioprine | 1 (0.3%) |